Suggestions
Bennett Shum
Improving public health by making medical-grade genomic tests accessible to all.
Bennett Shum is the co-founder and CEO of Genepath, a medtech startup focused on next-generation newborn screening.12 He is also an Adjunct Senior Lecturer at the UNSW School of Biomedical Sciences and an industry mentor for the UNSW Founders startup program.13
Background and Education::
- Shum trained at the Garvan Institute and Harvard Medical School.2
- He is an Adjunct Senior Lecturer at the University of New South Wales (UNSW).2
Contributions and Achievements::
- Shum helped implement genomic testing technology in hospitals across Australia.2
- He is passionate about developing genomic solutions that can save lives globally.2
- Genepath has pioneered research into next-generation newborn screening.1
- He is a leader in peer-reviewed research regarding targeted gene sequencing tests for newborn screening.2
- Shum's research interests include using genomic technologies for public health and understanding DNA variation through functional genomics.1
Genepath's Work in Newborn Screening::
- Genepath is working to expand population newborn screening programs through multidisciplinary research.1
- The company's expertise lies in bioinformatics, software engineering, and molecular genetics, which facilitates the use of next-generation DNA sequencing for newborn screening.2
- Genepath has designed next-generation sequencing platforms for newborn screening, including a targeted panel for treatable childhood genetic conditions and software designed for newborn screening.2
- Targeted gene sequencing was technically validated in 2017 and clinically validated for spinal muscular atrophy in 2023 and cystic fibrosis in 2022.2
- Feasibility and cost-effectiveness of high-throughput testing were achieved in 2023.2
- Genepath is researching parent attitudes toward targeted gene sequencing for newborn screening to determine whether this technology should be incorporated into newborn screening programs.1
- They are also investigating the cost-effectiveness of including familial hypercholesterolemia and biotinidase deficiency in newborn screening.1
Highlights
Oct 1 · genepath.au
Genomic Newborn Screening Research | World leading - Genepath
Jun 6 · genepathdx.com
GenePath Diagnostics
Aug 30 · nagra.com
OPENTV APPOINTS BEN BENNETT CHIEF OPERATING OFFICER ...
